Takeda to Continue Strategic Expansion with Operations in Brazil

Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) announced today it will establish a new commercial subsidiary in Brazil. The new subsidiary represents the 12th new strategic expansion since January 2009 including Canada, Spain, Portugal, Ireland, Mexico, Sweden, Norway, Denmark, Belgium, Luxembourg and Turkey.
“Combined with Takeda’s additional recent expansions, this opportunity will drive Takeda’s ability to maximize the potential of our pipeline in Brazil,” said Alan MacKenzie, Executive Vice President (EVP) International Operations, Takeda Pharmaceuticals International, Inc. “Brazil is an important country in the Latin American region for Takeda to ensure we are providing our products where patients need them.”

Brazil is the largest country in Latin America with a population of approximately 196 million people. The Brazilian pharmaceutical market accounts for more than 40 percent of the pharmaceutical sales throughout Latin America and is forecasted to grow by 8.5 percent every year until the year 2013.

The new subsidiary will import and commercialize Takeda products for the Brazil market. Upon establishment, Takeda will build the infrastructure necessary for success in the Brazilian pharmaceutical market.

About the new subsidiary in Brazil

Name: To be determined
Location: Sao Paulo, Brazil
Established: Planned for February 2010

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Takeda is enhancing its R&D pipeline by concentrating its management resources in the following selected core therapeutic areas: lifestyle-related diseases, oncology and urological diseases (including gynecology), central nervous system diseases (including bone and joint disorders), and gastroenterological diseases. For more information, please visit www.takeda.com.

Contacts:

Seizo Masuda
Takeda Pharmaceutical Company Limited
+81-3-3278-2037 (office)

Rebekah Childers
Takeda Pharmaceuticals International, Inc.
+1-224-554-6428